Author + information
- Markus Florian Krackhardt1,
- Matt Waliszewski2,
- Maxime Pons3,
- Francois Verdun4,
- Michel Pansieri5,
- Xabobe Flores Rios6,
- Fernando Lozano7,
- Michael Boxberger8 and
- Behrouz Kherad9
- 1Charite University Hospital Berlin, Augustenburger Platz, Germany
- 2B.Braun Vascular Systems, Berlin, Germany
- 3Clinique du Millénaire, Montpellier, France
- 4Cardiologie, Fondation de la maison du diaconat- Hôpital Albert Schweitzer, Colmar, France
- 5Centre Hospitalier d'Avigon, Avignon, France
- 6Complejo Hospitalario Universitario de A Coruña, Coruna, Spain
- 7University General Hospital of Ciudad Real, Ciudad Real, Spain
- 8B. Braun, Berlin, Germany
- 9Charite, berlin, Germany
Diabetes mellitus is known to be associated with worse clinical outcomes in patients with coronary artery disease (CAD) undergoing percutaneous coronary interventions (PCI) with drug-eluting stents (DES). Defining the optimal duration of dual antiplatelet therapy (DAPT) after DES implantation is still controversially discussed. The objective of this subgroup analysis of the all-comers ISAR 2000 registry was to assess the safety and efficacy of a short DAPT (<6 month) versus a longer DAPT (>6 month) in diabetic patients electively treated with the polymer-free sirolimus coated ultrathin strut drug eluting stent (PF-SES).
Patients who received the PF-SES were investigated in a multicenter all comers observational study. The primary endpoint was the 9-month target lesion revascularization (TLR) rate whereas secondary endpoints included the 9-month MACE and procedural success rates.
167 Patients were treated with DAPT for ≤ 6 month (S-DAPT group) and 350 patients underwent DAPT treatment for 12 month (L-DAPT group). There was no significant difference in the overall MACE rate (4.6% versus 3.1%, p=0.441), the 9-month accumulated stent thrombosis rates (0.8% versus 0.3%, p=0.51) or the accumulated rate of bleeding complications (5.3% versus 3.4%, p=0.341).
PF-SES are safe and effective in the daily clinical routine with low rates of TLR and MACE in diabetic patients with stable disease. Our data suggest that extending DAPT duration beyond 6 months does not improve MACE or TLR at 9 months in patients with stable CAD (Identifier NCT02629575).
CORONARY: Stents: Drug-Eluting